Mucin glycoprotein peptide backbone (MUC)

The peptide backbone of mucin glycoproteins, often referred to as apomucin, is the protein core of a large family of high-molecular-weight glycoproteins (MUC1–MUC24) that are essential for protecting epithelial surfaces (Wikipedia, 2024; NIH, 2024). These backbones are characterized by extensive tandem repeat sequences, known as the Variable Number of Tandem Repeats (VNTR) region, which are rich in serine, threonine, and proline residues that serve as sites for heavy O-glycosylation (Frontiers in Immunology, 2026; ResearchGate, 2022). In healthy tissues, this dense glycosylation masks the peptide core, providing lubrication and a physical barrier against pathogens and mechanical stress (Massive Bio, 2026; NIH, 2024). However, in many cancers, particularly adenocarcinomas, mucins undergo aberrant glycosylation and loss of cell polarity, leading to the exposure of the underlying peptide backbone and the creation of tumor-specific glycopeptide epitopes (NIH, 2024; NIH, 2019). This exposure makes the mucin peptide backbone a significant therapeutic target for immunotherapies, including monoclonal antibodies, vaccines, and CAR-T cells, which aim to exploit the differential glycosylation patterns to selectively eliminate malignant cells (DimaBio, 2024; NIH, 2024). Beyond oncology, the structure and production of these backbones are critical in inflammatory and obstructive diseases such as cystic fibrosis and asthma, where altered mucin properties contribute to disease pathology (ResearchGate, 2015; NIH, 2020).

Other names

ApomucinMucin protein coreMucin polypeptideVNTR regionMucin-1 peptide backboneVariable Number of Tandem Repeats region

Therapeutic strategies target the exposed peptide epitopes, particularly the Variable Number of Tandem Repeats (VNTR) region, which becomes accessible in cancer cells due to hypoglycosylation (Frontiers in Immunology, 2026; NIH, 2024). Monoclonal antibodies and CAR-T cells bind these neoepitopes to induce direct cell lysis or immune-mediated destruction, while vaccines stimulate the production of mucin-specific cytotoxic T lymphocytes (CTLs) to recognize and eliminate tumor cells (NIH, 2024; DimaBio, 2024).